MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Autoimmune & Inflammatory Diseases

09/242021

MSC CARs engineered with a CAR enhances immunosuppression

Mesenchymal Stromal Cells (MSCs), have been used in cell therapy for treatment of various inflammatory conditions. Chimeric Antigen Receptor (CAR) engineered MSCs have the potential to create an MSCs with higher immunosuppression activity and in-vivo persistence.

Read more
06/152021

ProGel delivers meds for long-term local effect

ProGel is a platform technology with a diverse spectrum of drug payloads, such as steroids, statins, antioxidants, opioids, chemotherapeutics, and hormones.  Ensign Pharmaceutical’s initial product focuses on managing osteoarthritis pain, incorporating a potent steroid, dexamethasone, into the formulation.

Read more
06/012021

Serine protease inhibitors treats eosinophilic esophagitis

A critical component of normal esophageal function is a protective epithelial barrier that prevents damage to the underlying tissue due to outside environment exposure such as foreign antigens and microorganisms.

Read more
05/252021

Novel mPGES-1 inhibitor targets pain, inflammatory diseases

It has been proposed that prostaglandin E2 (PGE2), known as the principal proinflammatory prostaglandin, is implicated in pain response and also plays a role in inflammatory diseases.

Read more
04/012021

Agmatine-based pain treatment avoids opioid addiction

The search for better analgesics has focused on non-addictive alternatives. Agmatine, the decarboxylated product of arginine, is a potential candidate for novel therapeutics.

Read more
04/012021

Humanized antibodies to treat diabetes, range of tissue injuries

SerpinB13 is a protease inhibitor linked to autoimmune inflammation and Type 1 diabetes (T1D).

Read more
03/302021

Non-viral formulation delivers lubricin genes

Post-traumatic osteoarthritis weakens the regulation of lubricin gene and increases shear stress within the joints.

Read more

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    542 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    555 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    556 days ago

Follow us! @DrugMw